• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

4 Conservative Dividend Stocks That Belong in Every Income Investors Portfolio

These blue chips pay shareholders handsomely in the form of dividends and share buybacks.
By HALE STEWART
Jul 21, 2018 | 12:00 PM EDT
Stocks quotes in this article: KO, MRK, PEP, PFE

I mentioned in a recent column that I think we're nearing the end of the current bull market. After all, a big first-half selloff is keeping the averages down for the year to date, the Federal Reserve is raising rates and the potential for economic shocks is increasing (largely thanks to escalating trade tensions). During these times, investors should consider selling positions with large gains and shifting assets into more conservative, established companies -- like the four below.

All four of these names have very strong cash flows that allow them to not only pay better than 3% dividends, but also to buy back stock. Two are consumer staples, a sector that's been the S&P 500's second-best performer over the past month (up 3.83%). The others are in health care, which has been the S&P 500's No. 3 best sector (+3%) during the past month. Here they are, listed in alphabetical order:

Coca-Cola (KO)

I don't know if there's a more quintessential American company than Coca-Cola -- a brand that's virtually intertwined with American cultural history. While the company's gross revenue has declined from $46.8 billion in 2013 to just $35.4 billion in 2017, KO still has tremendous cash flow and generates EBITDA equal to 25%-30% of gross revenue.

Coke currently yields 3.49%, has a 75.4% payout ratio and has raised its dividend for 55 consecutive years. The company has also purchased nearly $20 billion of its own stock since 2013 while paying out $28.4 billion in dividends.

KO is currently about halfway between its 52-week low and high, with the stock's price above its 200-day exponential moving average.

Merck & Co. (MRK)

Merck has been a powerhouse drug company for more than 50 years. It currently yields 3.05% and has a 45% payout ratio, although MRK has only raised its dividend for six consecutive years. And while gross revenue has declined slightly over the past 5 years -- falling from $44 billion in 2013 to $40 billion in 2017 -- MRK generates EBITDA equal to about 30% of gross revenue.

The pharmaceuticals giant also has great cash flow. Since 2013, MRK has purchased $26 million of its own stock and paid out nearly $20 billion in dividends. The stock has been in rally mode since late March, and is currently trading near its 52-week high.

PepsiCo (PEP)

Like Coca-Cola, PepsiCo is a part of U.S. culture, selling famous soft drinks like Pepsi and Mountain Dew, as well as snacks such a Doritos and Lay's potato chips.

Action Alerts PLUS holding PEP currently yields 3.29%, has a very safe 65.2% payout ratio and has increased its dividend for 45 straight years. Yes, gross revenue has fallen to $63 billion in 2017 from $66 billion in 2013, but PepsiCo's EBITDA equals nearly 20% of gross revenue.

Its cash flow is also impossibly strong, allowing the company to buy back nearly $18 billion of stock over the past five years while paying out nearly $20 billion in dividends.

PEP is currently trading about two-thirds of the way between its 52-week high and low, with the stock's price above its 200-day EMA.

Pfizer (PFE)

PFE is another stalwart U.S. drug manufacturer. Its gross revenue has risen from $51 billion in 2013 to $52 billion as of 2017, and it has the best free-cash flow of the all four of these stocks, with an EBITDA/gross revenue percentage in the high 30s.

That's allowed the company to buy back a whopping $37.5 billion stock and pay out nearly $35 billion in dividends since 2013. Pfizer currently has a 3.62% yield and a 45.9% payout ratio, although the company has only increased its dividend for the past eight years.

Lastly, the stock is near its 52-week high, with rising momentum.

The Bottom Line

All four names above pay shareholders handsomely in the form of dividends and share buybacks (which help to put a floor underneath stock prices). Each also has a beta below 1.0, which means it's less volatile than the S&P 500.

This combination of features makes all four of these stocks great choices for income investors.

(This article was sent July 16 to subscribers of TheStreet's Income Seeker, a product presenting the world of opportunities in fixed income and dividend stocks. Click here to learn more about Income Seeker and to receive articles like this each day from Nick McCullum, Hale Stewart, Peter Tchir, Jonathan Heller and others.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Jim Cramer manages as a charitable trust, is long PEP.

TAGS: Investing | U.S. Equity | Dividends | How-to

More from Investing

Marveling at the Market's Move? It's All About Momentum

James "Rev Shark" DePorre
Jan 19, 2021 4:41 PM EST

No news can explain the action -- whether the bears believe it or not.

Surface Oncology Is Set for Further Gains - How to Buy It

Bruce Kamich
Jan 19, 2021 3:25 PM EST

Here's our price objective.

My Preference With OneSpan Is Calls So I Can Define My Risk

Timothy Collins
Jan 19, 2021 2:36 PM EST

The last few post-earnings beat downs were greeted with optimism once traders got over the initial disappointment.

A Top Biotechnology Play for 2021

James "Rev Shark" DePorre
Jan 19, 2021 2:07 PM EST

Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.

Boot Barn Gets a Quant Upgrade: Do the Charts Fit?

Bruce Kamich
Jan 19, 2021 1:53 PM EST

Here's our latest analysis and trading strategy for the shares.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • 08:02 AM EST GARY BERMAN

    Tuesday Morning Fibocall for for 1/19/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login